Reclaimed at end of life
Tonnes as filed. Totals combine re-used, recycled and safely disposed, because filers place comparable activity in different columns.
category_row_disappeared. FY 2025-26 omits other, filed in this company's other years. Absence is not a reported zero.
reporting_boundary_changed. Reporting boundary changed across years: FY 2022-23 Standalone basis, FY 2023-24 Standalone, FY 2024-25 Standalone, FY 2025-26 Standalone. Year-on-year figures cover different entities.
| Category | FY 2022-23 | FY 2023-24 | FY 2024-25 | FY 2025-26 |
|---|---|---|---|---|
| Plastics including packaging | not filed | 2,800 | 3,053 | 0 |
| E-waste | not filed | 0 | 0 | 0 |
| Hazardous waste | not filed | 0 | 0 | 0 |
| Other waste | 1,415 | not filed | 0 | not filed |
| Total reclaimed | 1,415 | 2,800 | 3,053 | 0 |
Recycled or reused input material
Share of total material by value, per material line as the company named it. Each line carries its own denominator, so they are never summed or averaged.
| Input material, as filed | FY 2022-23 | FY 2023-24 | FY 2024-25 | FY 2025-26 |
|---|---|---|---|---|
| NA | not filed | not filed | 0.0% | not filed |
NIC codes filed
Products and services accounting for 90 percent of turnover, latest filing.
| Code | Description as filed | Share of turnover |
|---|---|---|
| 210 | The Company's primary products and services, accounting for 90% of its turnover, include the research, development, manufacturing, and sale of branded generics, generics, specialty medicines, and over the counter (OTC) pharmaceutical products. These offerings span a wide range of therapeutic areas such as dermatology, respiratory care, oncology, cardiology, diabetes management, gynecology, gastroenterology, and anti-infective treatments, among others. | 100.00% |
Source filings
| Year | Basis | Taxonomy | Turnover as filed |
|---|---|---|---|
| FY 2022-23 | Standalone basis | 2023-06-30 | 82,20,66,28,086 |
| FY 2023-24 | Standalone | 2024-04-30 | 78,91,11,90,000 |
| FY 2024-25 | Standalone | 2025-05-31 | 92,26,40,90,000 |
| FY 2025-26 | Standalone | 2026-02-28 | 84,40,09,90,000 |
Figures read from BRSR XBRL as filed. Nothing estimated or restated. How this works · Report an error